Unsolved questions and concerns about treatment of anti-neutrophil cytoplasm antibody-associated vasculitides.
The treatment strategy for vasculitis has changed dramatically over the last few years, but some major questions remain. Herein, after reviewing the literature, we provide answers to, or at least an analysis of, available evidence on 10 specific and practical questions concerning ANCA-associated vasculitis management.